Thornsberry C
MRL Pharmaceutical Services, Franklin, TN 37064, USA.
Pharmacotherapy. 1995 Jan-Feb;15(1 Pt 2):3S-8S.
Resistance of nosocomial and community-acquired pathogens to antimicrobial agents is a serious problem with significant clinical consequences. Microbiologic surveillance data, such as those provided by the National Nosocomial Infections Surveillance System, supply information on current nosocomial pathogens in the United States. Many species show resistance to commonly used antimicrobials and, in many cases, it is emerging resistance. Resistance in many gram-negative bacteria is caused by beta-lactamase production. Escherichia coli, the leading nosocomial pathogen, is capable of hyperproducing TEM-1 beta-lactamase. A novel form of resistance in Klebsiella pneumoniae and E. coli is caused by extended-spectrum cephalosporinases. Many Enterobacteriaceae can be induced to produce group 1 beta-lactamase by exposure to broad-spectrum cephalosporins and other beta-lactams. Thirty percent of Haemophilus influenzae isolates are resistant to ampicillin because of beta-lactamase production. Issues of concern in gram-positive species include multiple antimicrobial resistance in methicillin-resistant Staphylococcus aureus, enterococci, and coagulase-negative staphylococci, and increasing beta-lactam resistance in Streptococcus pneumoniae. To minimize the development of resistance, antimicrobials must be administered judiciously, and infection-control practices must be instituted and followed.
医院获得性病原菌和社区获得性病原菌对抗菌药物的耐药性是一个严重问题,具有重大临床后果。微生物监测数据,如国家医院感染监测系统提供的数据,可提供美国当前医院病原菌的信息。许多菌种对常用抗菌药物表现出耐药性,而且在很多情况下,耐药性正在出现。许多革兰氏阴性菌的耐药性是由β-内酰胺酶的产生引起的。医院主要病原菌大肠杆菌能够超量产生TEM-1β-内酰胺酶。肺炎克雷伯菌和大肠杆菌中一种新的耐药形式是由超广谱头孢菌素酶引起的。许多肠杆菌科细菌通过接触广谱头孢菌素和其他β-内酰胺类药物可被诱导产生1型β-内酰胺酶。30%的流感嗜血杆菌分离株因产生β-内酰胺酶而对氨苄西林耐药。革兰氏阳性菌中值得关注的问题包括耐甲氧西林金黄色葡萄球菌、肠球菌和凝固酶阴性葡萄球菌的多重抗菌药物耐药性,以及肺炎链球菌β-内酰胺耐药性的增加。为尽量减少耐药性的产生,必须合理使用抗菌药物,并制定和遵循感染控制措施。